Saturday 7 November 2026 Export AGEN’s income statement to Excel — free account

Agenus Inc.

AGEN Healthcare Biotechnology

Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.

Revenue: +4.14%
EPS: −99.0%
Free cash flow: −37.1%
Total debt: −28.6%

Quarter to September 2026, against a year earlier

7.13 0.69 +10.71%

Follow AGEN

Alert me

Market cap: $290.8M
P/E: 10.7×
Fwd P/E: 29.0×
Dividend yield: —
F-score: 4/9
Altman Z: −14.16
Beneish M: 12.57
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 36.28%

Capital & Financial Ratios $m

Size

Market Cap 290.84

Revenue ttm 133.95

Net income ttm 30.75

Free cash flow ttm (103.86)

Net debt Q (42.51)

Valuation

P/E 10.70

Forward P/E 29.00

Price / sales 3.33

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 0.73

Debt / equity Q (0.22)

Interest coverage Q 0.79

Growth

Revenue growth Q +4.14%

Operating income growth Q +351.00%

EPS, this year +114.08%

EPS, next year A −325.23%

Revenue, next year A +7.71%

EPS, past 5 yrs —

EPS, next 5 yrs A +32.54%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 42.82%

10-year low 10-year high

EV/Sales against its own 10 years 45.67%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	76	40	3	67
Receivables	26	0	7	—
Inventory	—	—	—	—
Other	2	2	123	—
	112	46	133	148

	2023	2024	2025	Q'26
Payables	61	61	83	47
ST’ Debt	0	3	45	—
Other	146	120	161	—
	256	221	323	204

Compound Annual Growth %

	10y	5y	3y
Sales	16.49%	5.31%	5.22%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.02 Actual 0.02

−1.78 −0.68 0.42 1.51 2.61

Q4 FY25 Beat +1.83

Q1 FY26 Miss −1.08

Q2 FY26 Miss −0.06

Q3 FY26 Met 0.00

Q4 FY26 — Mar 15

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.27	0.56	Beat by 1.83
Q1 FY26	2.10	1.02	Miss by 1.08
Q2 FY26	0.05	−0.01	Miss by 0.06
Q3 FY26	0.02	0.02	Met by 0.00
Q4 FY26	0.00	—	Reports 15 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.02	(0.01)	0.02	—	—
’25	(1.03)	(1.00)	1.94	(0.37)	0.00
’24	(3.04)	(2.52)	(3.08)	(2.04)	(10.59)
’23	(4.40)	(4.00)	(3.20)	(2.60)	(13.80)
’22	(3.80)	(3.40)	(3.80)	(4.80)	(15.60)
’21	(5.40)	(7.40)	14.40	(5.20)	(2.20)
’20	(6.20)	(5.60)	(5.60)	(4.00)	(21.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	34	35	31	—	—
’25	24	26	30	34	114
’24	28	24	25	27	103
’23	23	25	24	84	156
’22	26	21	23	28	98
’21	12	11	253	20	296
’20	15	27	15	31	88

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	(31)	(20)	—	—
’25	(26)	(20)	(15)	(17)	(77)
’24	(38)	(38)	(53)	(29)	(158)
’23	(59)	(60)	(65)	(40)	(224)
’22	(52)	(43)	(32)	(47)	(175)
’21	(43)	(56)	131	(23)	10
’20	(35)	(37)	(32)	(36)	(139)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	(31)	(20)	—	—
’25	(26)	(20)	(15)	(17)	(77)
’24	(38)	(39)	(53)	(29)	(159)
’23	(60)	(64)	(69)	(38)	(231)
’22	(57)	(52)	(48)	(50)	(206)
’21	(43)	(58)	109	(26)	(18)
’20	(35)	(38)	(32)	(36)	(143)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	23	43	37	150	88	296	98	156	103	114	134		+19.7%	123	116	129	+4.2%
	Gross margin, %	100.00	100.00	100.00	100.00	97.34	98.83	89.22	98.01	99.53	99.11	100.00		(0.9) pt	Powerpack Agenus Inc.’s next three years, line by line Analysts expect revenue to grow 4.2% a year to 2028 — slower than the 19.7% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(127)	(121)	(162)	(112)	(183)	(29)	(231)	(257)	(232)	(3)	31		(33.8%)
	EBT margin, %	(562.59)	(281.48)	(440.53)	(74.35)	(207.43)	(9.72)	(235.31)	(164.69)	(224.50)	(2.70)	22.96		+559.9 pt
	Net income	(127)	(121)	(162)	(112)	(183)	(29)	(231)	(257)	(232)	(3)	31		(33.8%)
Per share, $
Per share, $	Revenue	5.19	8.71	6.64	22.23	10.22	25.83	6.96	8.74	4.82	3.84	2.14		(3.3%)
	Earnings	(29.20)	(24.60)	(28.80)	(16.00)	(21.00)	(2.20)	(15.60)	(13.80)	(10.59)	0.00	0.67		n/m
	Cash flow	(18.37)	(19.15)	(23.67)	(2.77)	(16.13)	0.89	(12.45)	(12.53)	(7.37)	(2.60)	(1.66)		(19.5%)
	Capex	(2.88)	(0.61)	(0.65)	(0.69)	(0.40)	(2.46)	(2.21)	(0.37)	(0.03)	0.01	0.00		n/m
	Free cash flow	(21.24)	(19.76)	(24.32)	(3.46)	(16.53)	(1.57)	(14.65)	(12.90)	(7.40)	(2.58)	(1.66)		(20.9%)
	Book value	(8.99)	(15.41)	(31.51)	(34.28)	(24.52)	4.19	(3.90)	(8.29)	(14.27)	(9.34)	(1.79)		+0.4%
	Shares, m	4	5	6	7	9	11	14	18	21	30	43		+23.8%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.70		0.0
	P/S	15.75	7.98	7.04	3.59	6.11	2.45	6.77	1.83	0.57	0.82	3.33		5.3
	P/B	0.00	0.00	0.00	0.00	0.00	15.10	0.00	0.00	0.00	0.00	0.00		1.5
	EV/Sales	18.16	10.37	5.96	3.28	5.20	1.46	4.93	1.43	0.50	1.39	3.24		5.3
	EV/FCF	(4.43)	(4.58)	(1.63)	(21.06)	(3.22)	(23.89)	(2.34)	(0.97)	(0.32)	(2.06)	(4.19)		(6.4)
Cash, $m
Cash, $m	Operating cash flow	(80)	(94)	(131)	(19)	(139)	10	(175)	(224)	(158)	(77)	(104)		(0.4%)
	Capex	(13)	(3)	(4)	(5)	(3)	(28)	(31)	(7)	(1)	0	0		n/m
	Free cash flow	(92)	(97)	(135)	(23)	(143)	(18)	(206)	(231)	(159)	(77)	(104)		(2.0%)
Balance, $m
Balance, $m	Working capital	50	17	7	(36)	(16)	175	24	(143)	(176)	(190)	(55)		n/m
	Net debt	54	103	(40)	(48)	(80)	(293)	(180)	(63)	(7)	42	(43)		(2.9%)
	Shareholders’ equity	(39)	(76)	(175)	(231)	(211)	48	(55)	(148)	(306)	(278)	(112)		+24.3%
Returns, %
Returns, %	ROA	(63.72)	(81.86)	(116.37)	(73.95)	(97.94)	(7.09)	(50.09)	(67.62)	(84.20)	(0.04)	12.29		+63.7 pt
	ROIC	(444.11)	(240.08)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		+444.1 pt
	ROE	(805.04)	210.36	127.73	53.15	81.80	29.51	6,300.19	242.00	100.01	0.03	(14.99)		+805.1 pt
People
People	Employees	255	255	294	328	359	441	533	389	316	81	—		(12.0%)
	Revenue/emp, $m	0.09	0.17	0.13	0.46	0.25	0.67	0.18	0.40	0.33	1.41	—		+36.0%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
XFOR X4 Pharmaceuticals, Inc.	$304.4M	— (loss-making)	— (loss-making)	+63.12% (above 0%: growing)	n/m	+27.45% (above 0%: growing)	82.18%	(694.37%)	Compare
BNTC Benitec Biopharma Limited	$301.5M	— (loss-making)	— (loss-making)	−85.42% (below 0%: shrinking)	n/m	+38.90% (above 0%: growing)	0.00%	0.00%	Compare
GALT Galectin Therapeutics Inc.	$301.0M	— (loss-making)	—	—	n/m	+63.06% (above 0%: growing)	0.00%	0.00%	Compare
ENTA Enanta Pharmaceuticals, Inc.	$293.6M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
SCTX Scribe Therapeutics Inc.	$293.1M	—	—	—	n/m	—	100.00%	(489.83%)	Compare
AGEN Agenus Inc.	$290.8M	10.7×	27.7×	+4.14% (above 0%: growing)	−99.00% (below 0%: shrinking)	−37.06% (below 0%: shrinking)	100.00%	36.23%
KYTX Kyverna Therapeutics, Inc.	$285.1M	— (loss-making)	— (loss-making)	—	n/m	−27.06% (below 0%: shrinking)	—	0.00%	Compare
PRLD Prelude Therapeutics Incorporated	$283.7M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
FULC Fulcrum Therapeutics, Inc.	$280.8M	— (loss-making)	— (loss-making)	+27,018.64% (above 0%: growing)	n/m	−13.05% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$293.3M	—	—	+42.60%	—	+27.45%	100.00%	(60.02%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	1.35m	3.60m	6.54
2024	4.15m	2.88m	3.37
2023	5.86m	(1.54m)	20.39

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Agenus Inc. (AGEN) Latest News

6 Nov

Impact 3 · 10:47 AM · Zacks

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

Impact 3 · 9:00 AM · Business Wire

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

5 Nov

Impact 4 · 7:30 AM · Business Wire

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

Impact 3 · 4:14 PM · MarketBeat

Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones

2 Nov

Impact 3 · 6:42 AM · Business Wire

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer

25 Oct

Impact 4 · 7:00 AM · Business Wire

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

22 Oct

Impact 4 · 4:30 PM · Business Wire

Agenus to Provide Third Quarter 2026 Financial Report and Development Update

20 Oct

Impact 4 · 5:02 PM · MarketBeat

Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial

8 Oct

Impact 4 · 7:30 AM · Business Wire

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

3 Oct

Impact 4 · 10:50 AM · Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

2 Oct

Impact 4 · 9:00 AM

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

19 Sep

Impact 4 · 10:09 PM

Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing

10 Sep

Impact 4 · 7:30 AM

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

28 Aug

Impact 3 · 10:07 AM

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

26 Aug

Impact 4 · 10:05 AM

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

7 Aug

Impact 3 · 5:45 PM

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

6 Aug

Impact 4 · 7:30 AM

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

17 Jul

Impact 4 · 4:11 PM

Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing

14 Jul

Impact 4 · 11:57 AM

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Impact 4 · 10:17 AM · TheStreet

Agenus stock doubles as biotech narrows Phase 3 bet

Impact 4 · 6:15 AM

Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?

Impact 3 · 8:15 AM

Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?

13 Jul

Impact 4 · 2:25 PM · Stocktwits

AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment

Impact 4 · 12:53 PM · Proactive Investors

Agenus shares surge as company secures up to $340M to advance colon cancer trial

Impact 4 · 10:02 AM · MarketBeat

Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing

Impact 4 · 8:25 AM · InvestorsHub

Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)

Impact 4 · 7:46 AM · biopharmadive.com

Agenus surges on study pivot; Apnimed lines up an IPO

Impact 4 · 6:00 AM

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

6 Jul

Impact 4 · 7:30 AM

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

25 Jun

Impact 3 · 7:00 AM · Business Wire

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Agenus Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Agenus Inc. (AGEN) Latest News

6 Nov

5 Nov

2 Nov

25 Oct

22 Oct

20 Oct

8 Oct

3 Oct

2 Oct

19 Sep

10 Sep

28 Aug

26 Aug

7 Aug

6 Aug

17 Jul

14 Jul

13 Jul

6 Jul

25 Jun

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Agenus Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Agenus Inc. (AGEN) Latest News

6 Nov

5 Nov

2 Nov

25 Oct

22 Oct

20 Oct

8 Oct

3 Oct

2 Oct

19 Sep

10 Sep

28 Aug

26 Aug

7 Aug

6 Aug

17 Jul

14 Jul

13 Jul

6 Jul

25 Jun

Stockrow Weekly